دورية أكاديمية
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
| العنوان: | IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study |
|---|---|
| المؤلفون: | Barratt, Jonathan, Rovin, Brad, Wong, Muh Geot, Alpers, Charles E., Bieler, Stewart, He, Ping, Inrig, Jula, Komers, Radko, Heerspink, Hiddo J.L., Mercer, Alex, Noronha, Irene L., Radhakrishnan, Jai, Rheault, Michelle N., Rote, William, Trachtman, Howard, Trimarchi, Hernán, Perkovic, Vlado |
| المصدر: | PROTECT investigators , Barratt , J , Rovin , B , Wong , M G , Alpers , C E , Bieler , S , He , P , Inrig , J , Komers , R , Heerspink , H J L , Mercer , A , Noronha , I L , Radhakrishnan , J , Rheault , M N , Rote , W , Trachtman , H , Trimarchi , H & Perkovic , V 2023 , ' IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study ' , Kidney International Reports , vol. 8 , no. .... |
| سنة النشر: | 2023 |
| المجموعة: | University of Groningen research database |
| مصطلحات موضوعية: | dual endothelin angiotensin receptor antagonist, ethnicity, immunoglobulin A nephropathy, race, randomized controlled clinical trial, sparsentan |
| الوصف: | Introduction: Sparsentan is a novel single-molecule dual endothelin angiotensin receptor antagonist with hemodynamic and anti-inflammatory properties and is not an immunosuppressant. The ongoing phase 3 PROTECT trial examines sparsentan in adults with IgA nephropathy (IgAN). Methods: The PROTECT trial (NCT03762850) is a multicenter, international, randomized, double-blind, parallel-group, active-controlled study. The efficacy and safety of sparsentan versus the active control irbesartan is being evaluated in adults with biopsy-proven IgAN and proteinuria ≥1.0 g/d despite maximized treatment with an angiotensin-converting enzyme inhibitor (ACEi) and/or angiotensin receptor blocker (ARB) for at least 12 weeks. Blinded and aggregated baseline characteristics are reported descriptively and compared to contemporary phase 3 trials with patients with IgAN. Results: The primary analysis population includes 404 patients who were randomized and received study drug (median age, 46 years). Enrolled patients were from Europe (53%), Asia Pacific (27%), and North America (20%). Baseline median urinary protein excretion was 1.8 g/d. The range of estimated glomerular filtration rate (eGFR) was broad with the largest proportion of patients (35%) in chronic kidney disease (CKD) stage 3B. Before transitioning to study medication, mean systolic/diastolic blood pressure was 129/82 mm Hg, with the majority of patients (63.4%) receiving the maximum labeled ACEi or ARB dose. Patients in Asian versus non-Asian regions included a higher percentage of females, had lower blood pressures, and included lower proportions of patients with a history of hypertension and baseline antihypertensive treatment. Conclusions: Patient enrollment in PROTECT, with differing racial backgrounds and across CKD stages, will allow for important characterization of the treatment effect of sparsentan in patients with IgAN with proteinuria at high risk of kidney failure. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://research.rug.nl/en/publications/ef3e5c08-fad1-4a70-8ddd-9ee4c56a73d5Test |
| DOI: | 10.1016/j.ekir.2023.02.1086 |
| الإتاحة: | https://doi.org/10.1016/j.ekir.2023.02.1086Test https://hdl.handle.net/11370/ef3e5c08-fad1-4a70-8ddd-9ee4c56a73d5Test https://research.rug.nl/en/publications/ef3e5c08-fad1-4a70-8ddd-9ee4c56a73d5Test https://pure.rug.nl/ws/files/667840975/IgA_Nephropathy_Patient_Baseline_Characteristics_in_the_Sparsentan_PROTECT_Study.pdfTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.9A7D2468 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.ekir.2023.02.1086 |
|---|